Randomized trial · people
SS-31: walk distance rose with dose in 5-day MMPOWER trial
Checked against the paper Randomized trialPublished by PepVault
The takeaway
An early, short trial in adults with primary mitochondrial myopathy found walking distance improved with higher intravenous doses of elamipretide, without added safety concerns over 5 days. Larger, longer trials are still needed.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 36
- Published
- 2018
- Journal
- Neurology
What they tested
The team tested whether elamipretide (SS-31) is safe and improves exercise ability in adults with primary mitochondrial myopathy, a muscle disease confirmed by genetic testing in this trial.
How the study was done
A phase I/II, multicenter, randomized, double-blind, placebo-controlled trial in 36 adults with genetically confirmed primary mitochondrial myopathy. Participants got elamipretide into a vein at 0.01, 0.1 or 0.25 mg/kg/h, or placebo (a dummy infusion), for 2 hours in a dose-escalating order. The main measure was the 6-minute walk test (how far a person walks in 6 minutes) after 5 days.

What they found
People in the highest-dose arm walked an average of 64.5 m farther at day 5, compared with 20.4 m farther in the placebo group (p = 0.053). Walk distance rose with dose across the elamipretide arms (p = 0.014). After adjusting for other factors that could affect results, the change was 51.2 m for the highest dose vs 3.0 m for placebo (p = 0.0297). No significant differences showed up in the other efficacy measures or in safety.
What it doesn’t show
This was a small trial with only 5 days of treatment, so it can't show longer-term benefit or safety. Elamipretide was given into a vein, and the other measures, such as exercise testing, symptoms and blood and urine markers, showed no significant change.
The paper
Karaa et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018.
The compound
More studies on SS-31
- SS-31 (elamipretide) eye drops missed main vision goal in LHON trialRandomized trial · people · 2024
- SS-31: wearable data grouped responders with 100% accuracyRandomized trial · people · 2023
- SS-31: no 12-week benefit, walk gains by 36 weeks open-labelRandomized trial · people · 2021
- SS-31 raised muscle ATP capacity after one dose in older adultsRandomized trial · people · 2021
- SS-31: less kidney hypoxia after renal artery stenting in pilotRandomized trial · people · 2017
- SS-31 did not significantly cut infarct size in EMBRACE STEMIRandomized trial · people · 2016
- Every study on SS-31
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.